Photostability of pitavastatin-A novel HMG-CoA reductase inhibitor

被引：21

作者：

Grobelny, Pawel ^{[2
]}

Viola, Giampietro ^{[3
]}

Vedaldi, Daniela ^{[4
]}

Dall'Acqua, Francesco ^{[4
]}

Gliszczynska-Swiglo, Anna ^{[5
]}

Mielcarek, Jadwiga ^{[1
]}

机构：

[1] Poznan Univ Med Sci, Dept Inorgan & Analyt Chem, PL-60780 Poznan, Poland

[2] Poznan Univ Med Sci, Dept Pharmaceut Technol, PL-60780 Poznan, Poland

[3] Univ Padua, Dept Pediat, Oncohematol Lab, I-35131 Padua, Italy

[4] Univ Padua, Dept Pharmaceut Sci, I-35128 Padua, Italy

[5] Poznan Univ Econ, Fac Commod Sci, PL-60967 Poznan, Poland

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2009年 / 50卷 / 04期

关键词：

Statins; HMG-CoA reductase inhibitors; Pitavastatin; Photostability; Photodegradation; STATINS; STABILITY; WATER; ROSUVASTATIN; FORMULATION; SAFETY; PLASMA;

D O I：

10.1016/j.jpba.2008.10.004

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

The photostability of pitavastatin, an HMG-CoA reductase inhibitor used in the treatment of hypercholesterolemia, was investigated. The sample solution was exposed to UV-A radiation and the photodegradation process was monitored by means of spectro photometric method and HPLC-DAD. Pitavastatin was shown to be photolabile and its photodegradation reaction followed the first-order kinetics with the rate constant k = 3.54 x 10(-4) +/- 9.43 x 10(-6) s(-1). The chromatograms revealed the presence of four major photoproducts (PP-1-PP-4). The separated and isolated photolytic products were identified using a mass spectrometer coupled with a time of flight (TOF) analyzer. The main reaction observed during exposure to radiation of pitavastatin was photocyclisation leading to formation of four-ring photoproducts. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：597 / 601

页数：5

共 50 条

[31] HYPERKALEMIA DURING TREATMENT WITH HMG-COA REDUCTASE INHIBITOR
EDELMAN, S
WITZTUM, JL
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (18): : 1219 - 1220
[32] PRAVASTATIN SODIUM, A NEW HMG-COA REDUCTASE INHIBITOR
RAASCH, RH
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (04): : 388 - 394
[33] INHIBITION OF CHOLESTEROL ABSORPTION BY HMG-COA REDUCTASE INHIBITOR
MIETTINEN, TA
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 : S19 - S21
[34] Rosuvastatin - A new HMG-CoA reductase inhibitor for hypercholesterolemia
Roach, AE
Tsikouris, JP
Haase, KK
FORMULARY, 2002, 37 (04) : 179 - +
[35] Design of Tripeptides as a Competitive Inhibitor for HMG-CoA Reductase
Pak, Valeriy V.
Kwon, Dae Yong
Khojimatov, Olim K.
Pak, Aleksandr, V
Sagdullaev, Shomansur Sh
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2021, 27 (03) : 1923 - 1931
[36] HMG-CoA reductase inhibitor treatment in renal insufficiency
Wanner, C
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (10) : 1951 - 1952
[37] TOWARDS A NEW TYPE OF HMG-COA REDUCTASE INHIBITOR
BARTH, M
BELLAMY, FD
RENAUT, P
SAMRETH, S
SCHUBER, F
TETRAHEDRON, 1990, 46 (19) : 6731 - 6740
[38] The novel HMG-CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)
Tokoro, T
Wang, JY
Kitajima, I
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2004, 124 (03): : 121 - 126
[39] HMG-CoA reductase inhibitor-induced impotence
Halkin, A
Lossos, IS
Mevorach, D
ANNALS OF PHARMACOTHERAPY, 1996, 30 (02) : 192 - 192
[40] Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
Bischoff, H
Angerbauer, R
Bender, J
Bischoff, E
Faggiotto, A
Petzinna, D
Pfitzner, J
Porter, MC
Schmidt, D
Thomas, G
ATHEROSCLEROSIS, 1997, 135 (01) : 119 - 130

← 1 2 3 4 5 →